Device and method for in vivo photoacoustic diagnosis and photothermal purging of infected blood

Patent metadata

Field	Value
Publication number	US-2023355101-A1
Application number	US-202318215635-A
Country	US
Kind code	A1
Filing date	Jun 28, 2023
Priority date	Sep 25, 2012
Publication date	Nov 9, 2023
Grant date	—

Abstract

A method of non-invasively detecting and purging bacterial cells using a modified photoacoustic in vivo flow cytometer device is described herein. In particular, a method of detecting bacterial cells by analyzing photoacoustic pulses emitted in response to laser pulses from a pulsed laser source and/or selectively destroying the detected bacterial cells using a non-linear photothermal response induced by a high-energy laser pulse is described herein.

First claim

What is claimed is:

1 . A method for in vivo integrated photoacoustic and photothermal nano-theranostics of a plurality of circulating target objects in blood, lymph, and other vessels of a living organism, comprising:
generating at least one series of consecutive diagnostic laser pulses with low energy; delivering the laser pulses to the plurality of circulating target objects; detecting one or more of laser-induced photoacoustic, photothermal, fluorescence, Raman, high speed transmission, or scattering light signals from the plurality of circulating target objects using ultrasound transducers or photodiodes; analyzing the detected signals to determine at least one characteristic of the plurality of circulating target objects; and triggering, using the detected signals, a therapeutic laser pulse of high energy at the same or a different wavelength to produce laser-induced photothermal nanobubbles destroying the plurality of circulating target objects.

2 . The method of claim 1 , the method further comprising monitoring a frequency of detection of the photoacoustic, photothermal, fluorescence, Raman, high speed transmission, or scattering light signals to control the efficacy of photothermal destruction of the plurality of circulating target objects using the frequency of detection.

3 . The method of claim 1 , wherein the method provides early diagnosis and treatment of metastasis, infection, viruses, clots, thrombosis, plaques, malaria, inflammations, immunodeficiency disorders, or biofilm-associated S. aureus bone infection including antibiotic-resistant strains.

4 . The method of claim 1 , wherein photoacoustic signals emitted by the plurality of circulating target objects result from single photon absorption, two photon absorption, multi-photon absorption, Coherent Anti-Stokes Raman Scattering (CARS), and/or combinations thereof.

5 . The method of claim 1 , wherein the at least one characteristic of the plurality of circulating target objects is a type, concentration, target speed, total circulating blood or lymph volume, and/or combinations thereof.

6 . The method of claim 5 , wherein the target speed is determined by a width of the detected signal, a time delay between two detected signals produced by a single target measured at two locations of two distinct laser pulses applied to a known separation distance, or a frequency shift of a signal.

7 . The method of claim 5 , wherein the total circulating blood or lymph volume is determined using a degree of dilution of one or more absorbing dyes, or blood cells extracted from the organism, labeled using the absorbing dyes, and reintroduced to the organism.

8 . The method of claim 1 , wherein the plurality of circulating target objects are one or more of normal, apoptotic and necrotic white blood cells, neutrophils, lymphocytes, aggregated red blood cells, infected cells, inflamed cells, stem cells, dendritic cells, platelets, metastatic melanoma cells, leukemia, breast cancer, prostate cancer, ovarian cancer, testicular cancer, fungal cells, protozoa, microorganisms, pathogens, animal cells, plant cells, leukocytes activated by various antigens during an inflammatory reaction, red blood cells in lymphatic vessels, and/or combinations thereof.

9 . The method of claim 1 , wherein the plurality of circulating target objects possess intrinsic cell-specific markers selected from the group consisting of hemoglobin (Hb), HbH, HbO, metHb, HbCN, HbS, HbCO, HbChr, myoglobins, hemozoin, bilirubin, catalase, porphyrins, flavins, and/or combinations thereof.

10 . The method of claim 1 , wherein the method uses a label-free approach at NIR wavelengths near 740 nm for non-toxic and noninvasive diagnosis and killing of skin infections including individual unlabeled S. aureus cells with a laser wavelength corresponding to a peak absorption of the S. aureus cells.

11 . The method of claim 1 , wherein the plurality of circulating target objects are in mammals, reptiles, birds, amphibians, fish, plants, fungi, mollusks, insects, arachnids, annelids, arthropods, roundworms, and flatworms.

12 . The method of claim 1 , wherein the plurality of circulating target objects are contrast agents selected from the group consisting of indocyanine green dye, melanin, fluorescein isothiocyanate (FITC) dye, evans blue dye, lymphazurin dye, trypan blue dye, methylene blue dye, propidium iodide, Annexin, Oregon Green, C3, Cy5, Cy7, Neutral Red dye, phenol red dye, AlexaFluor dye, Texas red dye, dendrimers, aquasomes, lipopolyplexes, nanoemulsions, perfluorocarbon, polymeric nanoparticles, microbubbles, and/or combinations thereof.

13 . The method of claim 1 , wherein one or more microbubbles are loaded with contrast dyes or nanoparticles or are conjugated with PEG-coated gold nanoshells leading to laser-induced overheating and microbubble formation.

14 . The method of claim 1 , wherein the plurality of circulating target objects are labeled by contrast agents that are functionalized with a targeting agent comprising antibodies, proteins, folates, ligands for specific cell receptors, peptides, vitamins, wheat germ agglutinin, and/or combinations thereof.

15 . The method of claim 14 , wherein the ligands are specific to folate, epithelial cell adhesion molecule (Ep-CAM), Hep-2. PAR, CD44, epidermal growth factor receptor (EGFR); PCA, receptors of cancer cells, stem cells, chitin receptors of yeasts, specific to blood or lymphatic cell, endothelial markers, polysaccharide and siderophore receptors of bacteria, or antibody specific for proteins highly expressed in bacteria but absent in mammalian cells.

16 . A theranostic device for detection and treatment of a plurality of circulating target objects in blood, lymph, and other vessels of a living organism, the theranostic device comprising:
a laser for generating one or more laser pulses with low light energy and therapeutic pulses of high light energy; an optical module consisting of optical parametric oscillators, optical crystals, etalons, filters, Bragg reflector, and/or Raman shifters; one or more ultrasound transducers or photodiodes having one or more amplifiers for receiving laser-induced photoacoustic, photothermal, fluorescence, high speed transmission, Raman, or light scattering signals from the plurality of circulating target objects; a data recording system consisting of a boxcar device, a video camera to record a display of an oscilloscope electrically connected to the one or more ultrasound transducers or photodiodes, or a high-speed analog-to-digital board; and a computer with stored data analysis software configured to:
analyze signal patterns of the detected signals;
trigger, using the detected signals, therapeutic pulses of high light energy to produce nanobubbles destroying the plurality of circulating target objects irrespective of their drug resistance status; and
monitor a frequency of detection of the photoacoustic, photothermal, fluorescence, Raman, or scattering signals induced by the low energy laser pulses to control the efficacy of photothermal-based destruction of the plurality of circulating target objects using the frequency of detection.

17 . The device of claim 16 , wherein the laser is a diode pulse laser or modulated continuous radiation in the X-ray spectrum (1-10A), visible-infrared range (0.4 um-20 um), the terahertz spectra (20-1000 um) or the microwave spectra (0.5 mm-3 cm) having a pulse width ranging between 0.1 ps to about 1000 ns; a wavelength ranging between about 600 nm to about 2500 nm, a pulse rate ranging between 1 Hz and 500,

Assignees

• Bioventures Llc

Inventors

• Smeltzer Mark S
• Zharov Vladimir
• Galanzha Ekaterina

Classifications

• A61B5/0095 Primary

  by applying light and detecting acoustic waves, i.e. photoacoustic measurements · CPC title

• G01N33/569 Primary

  for microorganisms, e.g. protozoa, bacteria, viruses · CPC title

• G01N33/48728

  Investigating individual cells, e.g. by patch clamp, voltage clamp (investigating individual particles in general G01N15/10) · CPC title

• A61B5/14525

  using microdialysis · CPC title

• A61B5/4839

  combined with drug delivery · CPC title